Dasatinib
Established medicineAlso known as Phyrago, Sprycel, BMS dasatinib, Dasatinibum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: DASATINIB (NDA021986)
Label change: DASATINIB (NDA216099)
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Generic approval: DASATINIB (ANDA219579)
Improving Physical Ability and Cellular Senescence Elimination in HIV
Indication expansion: DASATINIB (NDA216099)
The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs.
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP)… Show full indicationShow less
Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy. Sprycel is indicated for the treatment of adult patients with: newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase; chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate; Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes6
Journals, researchers & institutions
- Anti-cancer drugs1
- Cancer1
- EBioMedicine1
- International journal of molecular sciences1
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer1
- Leukemia1
- Apperley JF1
- Azzoli CG1
- Baccarani M1
- Belotserkovskaya EV1
- Beumer JH1
- Bogdanova DA1
- Borger DR1
- Cervantes F1
- Almazov National Research Centre1
- Amsterdam University Medical Center1
- Barshop Institute for Longevity and Aging Studies1
- Burnett School of Biomedical Sciences1
- Case Western Reserve University1
- Centre Hospitalier de Versailles1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Dasatinib, with an overlapping disease area.
Acts on the same molecular target as Dasatinib, with an overlapping disease area.
Studied across 3 of the same disease areas as Dasatinib in the shared literature.
Studied across 2 of the same disease areas as Dasatinib in the shared literature.
Studied across the same disease area as Dasatinib in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.